FDA Approval Of Awiqli Adds New Dimension To Novo Nordisk Story [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
FDA approves Awiqli, a once weekly basal insulin, for adults with type 2 diabetes. The product is based on insulin icodec abae and is intended to reduce injection frequency versus daily basal insulin. Novo Nordisk, ticker CPSE:NOVO B, plans a nationwide US launch in the second half of 2026. Novo Nordisk, CPSE:NOVO B, is a major player in diabetes care, and Awiqli adds a new option to its insulin portfolio. Weekly dosing addresses one of the significant practical challenges in diabetes management: ongoing adherence to treatment plans that often involve multiple daily injections. For investors, the planned US rollout of Awiqli in the second half of 2026 introduces a product milestone to track within the company's core franchise. The approval also broadens Novo Nordisk's toolkit in type 2 diabetes, giving it another branded asset to position with healthcare providers and payers as the launch approaches. Stay updated on the most important news stories for Novo Nordisk by adding
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Vaxess Technologies raises $50m, rebrands to Terrestrial Bio [Yahoo! Finance]Yahoo! Finance
- Eli Lilly vs Novo Nordisk: Which Obesity Drug Stock Is the Better Buy? [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk: A Comeback Story In The World's Fastest-Growing Drug Market [Seeking Alpha]Seeking Alpha
- Hims & Hers shifts business model after Novo deal [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 3/27/26 - Form 6-K
- 3/27/26 - Form 6-K
- 3/26/26 - Form 6-K
- NVO's page on the SEC website